IDiyas

For the Inventor, By the Inventor

San Francisco, CA, United States of America

Tamie Chilcote

USPTO Granted Patents = 22 

Average Co-Inventor Count = 3.2

ph-index = 9

Forward Citations = 243(Granted Patents)


Location History:

  • South San Francisco, CA (US) (2010)
  • San Francisco, CA (US) (2007 - 2022)

Company Filing History:

goldMedal9 out of 9 
 
Activesite Pharmaceuticals, Inc.
 patents
silverMedal6 out of 202 
 
Elan Pharmaceuticals, Inc.
 patents
bronzeMedal3 out of 7 
 
Neotope Biosciences Limited
 patents
4. 3 out of 15,458 
 
University of California
 patents
5. 3 out of 8 
 
Rezolute, Inc.
 patents
6. 2 out of 57 
 
Prothena Biosciences Limited
 patents
7. 1 out of 2 
 
The Trustees of Flinders University
 patents
8. 1 out of 72 
 
Joslin Diabetes Center, Inc.
 patents
9. 1 out of 80 
 
Elan Pharma International Limited
 patents
10. 1 out of 832,680 
Other
 patents
where one patent can have more than one assignee

Years Active: 2007-2025

Loading Chart...
22 patents (USPTO):
1. 12240818 - Crystalline forms of plasma kallikrein inhibitors (2025-03-04),
2. 11306061 - Crystalline forms of plasma kallikrein inhibitors (2022-04-19),
3. 11267790 - Processes for preparing plasma kallikrein inhibitors (2022-03-08),
4. 9879071 - Antibodies to alpha synuclein (2018-01-30),
5. 9206123 - Prodrugs of inhibitors of plasma kallikrein (2015-12-08),
6. 9034337 - Treatment and delay of outset of synucleinopathic and amyloidogenic disease (2015-05-19),
7. 8691861 - Prodrugs of inhibitors of plasma kallikrein (2014-04-08),
8. 8673593 - Antibodies to alpha-synuclein (2014-03-18),
9. 8658685 - Methods for treatment of kallikrein-related disorders (2014-02-25),
10. 8609866 - Prodrugs of inhibitors of plasma kallikrein (2013-12-17),
11. 8506959 - Prevention and treatment of synucleinopathic and amyloidogenic disease (2013-08-13),
12. 8258170 - Inhibitors of plasma kallikrein (2012-09-04),
13. 8148089 - Alpha-synuclein kinase (2012-04-03),
14. 8147833 - Prevention and treatment of synucleinopathic and amyloidogenic disease (2012-04-03),
15. 8092801 - Prevention and treatment of synucleinopathic and amyloidogenic disease (2012-01-10),

Title: Tamie Chilcote: Innovator in Pharmaceutical Patents

Introduction

Tamie Chilcote, located in San Francisco, CA, is a prominent inventor with a remarkable portfolio of 22 patents. His innovative contributions primarily focus on the development of pharmaceutical compositions and novel chemical compounds.

Latest Patents

Among Tamie Chilcote's latest patents are the crystalline forms of plasma kallikrein inhibitors, specifically the pure crystalline forms of 1-benzyl-N-(4-carbamimidoylbenzyl)-1H-pyrazole-4-carboxamide acetate. He has also developed an amorphous form and provided methods for making these compositions, showcasing his commitment to advancing pharmaceutical science.

Career Highlights

Chilcote has worked with notable companies in the pharmaceutical industry, including Activesite Pharmaceuticals, Inc. and Elan Pharmaceuticals, Inc. His work in these organizations has significantly contributed to the development of impactful medical solutions.

Collaborations

Throughout his career, Tamie has collaborated with esteemed professionals, including Sukanto Sinha and Dale Bernard Schenk. These partnerships have likely enhanced his research and led to the successful realization of several innovative inventions.

Conclusion

Tamie Chilcote exemplifies a dedicated inventor in the pharmaceutical field with a strong history of innovation and collaboration. His ongoing work continues to shape the landscape of medical treatments and pharmaceutical compositions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…